Ontralfy is a drug owned by Fidelity Biopharma Co Usa. It is protected by 2 US drug patents filed from 2024 to 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 07, 2042. Details of Ontralfy's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12263158 | Tizanidine liquid preparation and use thereof |
May, 2042
(16 years from now) | Active |
| US12042484 | Tizanidine liquid preparation and use thereof |
May, 2042
(16 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Ontralfy's patents.
Latest Legal Activities on Ontralfy's Patents
Given below is the list of recent legal activities going on the following patents of Ontralfy.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification | 13 May, 2025 | US12263158 |
| Mail Patent eCofC Notification | 13 May, 2025 | US12263158 |
| Patent eCofC Notification | 13 May, 2025 | US12263158 |
| Recordation of Patent eCertificate of Correction | 13 May, 2025 | US12263158 |
| Post Issue Communication - Certificate of Correction | 30 Apr, 2025 | US12263158 |
| Post Issue Communication - Certificate of Correction | 21 Apr, 2025 | US12263158 |
| Patent eGrant Notification | 01 Apr, 2025 | US12263158 |
| Email Notification | 01 Apr, 2025 | US12263158 |
| Recordation of Patent eGrant | 01 Apr, 2025 | US12263158 |
| Recordation of Patent Grant Mailed | 01 Apr, 2025 | US12263158 |
US patents provide insights into the exclusivity only within the United States, but
Ontralfy is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Ontralfy's family patents as well as insights into
ongoing legal events
on those patents.
Ontralfy's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Ontralfy's generic launch date based on the expiry of its last outstanding patent is estimated to be May 07, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ontralfy Generic API suppliers:
Tizanidine Hydrochloride is the generic name for the brand Ontralfy. 23 different companies have already filed for the generic of Ontralfy, with Ani Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Ontralfy's generic
Alternative Brands for Ontralfy
There are several other brand drugs in the same treatment category as Ontralfy. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Metacel Pharms Llc |
| |||
About Ontralfy
Ontralfy is a drug owned by Fidelity Biopharma Co Usa. Ontralfy uses Tizanidine Hydrochloride as an active ingredient. Ontralfy was launched by Fidelity in 2024.
Approval Date:
Ontralfy was approved by FDA for market use on 12 December, 2024.
Active Ingredient:
Ontralfy uses Tizanidine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Tizanidine Hydrochloride ingredient
Dosage:
Ontralfy is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 2MG BASE/5ML | SOLUTION | Prescription | ORAL |